Keeping Pneumonia's Vaccines Effective

Erdmann, Jeanne

doi:10.1016/j.chembiol.2010.10.004

Cited by 1 publication

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Capsule-based (23- valent) vaccines have been relatively successful in providing protection to adults, and protein-conjugated-carbohydrate-based (7-valent) vaccines have recently provided considerable protection to infants in developed countries [6,7]. Nevertheless, serotypes not included in the 7-valent vaccine appeared rapidly in clinical isolates [10], prompting the development of new 10- and 13-valent conjugated vaccines tailored to the prevalent clinical isolates in different regions [6,7]. Ominously, in parallel to vaccine evasion, resistance of S. pneumoniae clinical isolates to multiple antibiotics has started to increase at alarming rates [11-13].…”

Section: Recent Trends In Vaccine Development Against Pneumococcal Prmentioning

confidence: 99%

Recent advances in pneumococcal peptidoglycan biosynthesis suggest new vaccine and antimicrobial targets

Sham

Tsui

Land

et al. 2012

Current Opinion in Microbiology

View full text Add to dashboard Cite

Streptococcus pneumoniae is a serious human respiratory pathogen that has the capacity to evade capsule-based vaccines and to develop multidrug antibiotic resistance. This review summarizes recent advances in understanding the mechanisms and regulation of peptidoglycan (PG) biosynthesis that result in ellipsoid-shaped, ovococcus Streptococcus cells. New results support a two-state model for septal and peripheral PG synthesis at mid-cell, involvement of essential cell division proteins in PG remodeling, and mid-cell localization of proteins that organize PG biosynthesis and that form the protein translocation apparatus. PG biosynthesis proteins have already turned up as promising vaccine candidates and targets of antibiotics. Properties of several recently characterized proteins that mediate or regulate PG biosynthesis suggest a source of additional targets for therapies against pneumococcus.

show abstract